Inspire Medical Systems Inc
F:2DR

Administrador de listas de seguimiento
Inspire Medical Systems Inc Logo
Inspire Medical Systems Inc
F:2DR
Lista de seguimiento
Precio: 36,2 EUR 1,69% Mercado cerrado
Capitalización de mercado: €1,08 B

Inspire Medical Systems Inc
Relación con Inversores

Inspire Medical Systems makes an implantable device that treats obstructive sleep apnea, a condition where the airway repeatedly closes during sleep. Its system works like a small pacemaker for breathing: a surgeon implants it under the skin, and it sends mild stimulation to a nerve that helps keep the airway open at night. The company’s main product is this therapy system, along with the tools and support needed to implant and use it. Its customers are mostly hospitals, sleep surgeons, and ear, nose, and throat specialists who select and implant the device for patients who have not done well with standard sleep apnea treatments such as CPAP. Inspire makes money by selling the device system and related components through the medical device supply chain, usually tied to the implantation procedure. In practice, the company sits between the doctor who diagnoses sleep apnea and the hospital or surgery center that performs the implant. What makes the business different is that it is not a broad sleep-apnea supplier or a disposable-device maker. It is focused on one specific treatment option for one specific patient group: people with moderate to severe obstructive sleep apnea who need an implanted alternative to masks and machines. That narrow focus gives it a clear role in sleep medicine and makes its business depend on physician adoption, patient selection, and reimbursement for an implanted therapy.

Mostrar más
Cargando...
No hay acciones seleccionadas

Compara la rentabilidad de la acción con su índice de referencia y sus competidores. Obtén información sobre su rendimiento relativo a lo largo del tiempo.

Selecciona una acción para comparar
Última conferencia de resultados
Periodo fiscal
Q1 2026
Fecha de la conferencia
4 may., 2026
Resumen con IA
Q1 2026

Revenue: First-quarter revenue rose 1.6% to $204.6 million, but management said coding, reimbursement uncertainty, and the WISeR program reduced revenue by about $20 million.

Guidance cut: The company lowered full-year 2026 revenue guidance to $825 million to $875 million and now expects a $120 million to $150 million total hit from reimbursement-related issues and WISeR.

Q2 pressure: Management expects the hardest near-term impact in the second quarter, with revenue expected to be down 9% to 11% year over year and an adjusted operating loss of $10 million to $15 million.

Coding progress: Medicare saw progress with a new C-code for Inspire V procedures, but commercial payer coding remains messy and is slowing prior authorizations and patient flow.

Growth reset: Management still believes the disruption is temporary, expects sequential improvement in the second half of 2026, and reiterated a return to growth in 2027.

Cash strength: The balance sheet stayed strong with no debt and $400 million in cash and investments, while operating cash flow improved to $12.8 million.

Datos financieros clave
Revenue
$204.6 million
Revenue impact from coding, reimbursement, and WISeR
approximately $20 million
Operating cash flow
$12.8 million
Cash and investments
$400 million
Adjusted EBITDA margin
17.5%
Diluted EPS
loss of $0.39
Adjusted diluted EPS
$0.10
Effective tax rate
571.2%
Adjusted effective tax rate
25.7%
Weighted average diluted shares outstanding
approximately 29.4 million
U.S. territories
284
U.S. field clinical representatives
288
Field clinical rep hires
13
Revision rate
1.7%
EXPAND rate
less than 1%
Patients treated since inception
over 135,000
Grabación de la conferencia de resultados
Otras conferencias de resultados

Dirección

Mr. Timothy P. Herbert
Founder, Chairman, CEO & President
No hay biografía disponible
Mr. Richard J. Buchholz
Chief Financial Officer
No hay biografía disponible
Mr. Randall A. Ban
Chief Commercial Officer
No hay biografía disponible
Dr. Charisse Y. Sparks FAAOS, M.D.
Chief Medical Officer
No hay biografía disponible
Mr. Carlton W. Weatherby
Chief Strategy Officer
No hay biografía disponible
Mr. John C. Rondoni
Chief Technology Officer
No hay biografía disponible
Ms. Ezgi Yagci
Vice President of Investor Relations
No hay biografía disponible
Mr. Bryan K. Phillips J.D.
Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary
No hay biografía disponible
Ms. Melissa J. Mann
Chief People Officer
No hay biografía disponible
Mr. Ivan Lubogo
Senior Vice President of U.S. Sales
No hay biografía disponible

Contactos

Dirección
MINNESOTA
Golden Valley
5500 Wayzata Blvd Ste 1600
Contactos
+17639575037.0
www.inspiresleep.com
Obtén análisis impulsados por IA para cualquier empresa o tema.
Abrir Asistente de IA

El valor intrínseco es de vital importancia y es la única forma lógica de evaluar el atractivo relativo de las inversiones y los negocios.

Warren Buffett